Mode
Text Size
Log in / Sign up

AIM-CHD system improves LDL-C target attainment to 71% in coronary heart disease patientsAI system helps heart patients hit cholesterol and blood pressure goals

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider AI-enhanced systems to improve LDL-C and blood pressure targets in coronary heart disease management.

This randomized clinical trial enrolled 1100 adults with confirmed coronary heart disease (CHD) to evaluate an artificial intelligence-enhanced management system (AIM-CHD). The AIM-CHD intervention included automated multi-source data capture, guideline-directed risk stratification, and closed-loop feedback via smartphone. The primary comparison was against usual care over a 3-month follow-up period.

At 3 months, the AIM-CHD group achieved an LDL-C level of 60.4 ± 23.4 mg/dL compared to 63.7 ± 26.0 mg/dL in the control group (adjusted mean difference -3.2 mg/dL; 95% CI, -6.2 to -0.3; p = 0.03). Regarding secondary outcomes, LDL-C target attainment (< 70 mg/dL) was higher in the intervention group (71%) compared to usual care (64%; RR, 1.10; 95% CI, 1.01-1.20; p = 0.03). Blood pressure target attainment (< 130/80 mm Hg) was also higher in the intervention group (45%) than in the control group (35%; RR, 1.27; 95% CI, 1.09-1.48; p = 0.002).

No significant differences were observed between groups regarding HbA1c, BMI, or medication adherence. Safety data and adverse events were not reported. The study is limited by its single-center design and short follow-up period of 3 months. These findings suggest that AIM-CHD may be a viable tool for improving lipid and blood pressure management in CHD patients.

If you have heart disease, keeping your cholesterol and blood pressure in check is a big deal. But it's not always easy. A new study shows that an artificial intelligence (AI) system might give you a helpful nudge.

Researchers in China tested an AI-enhanced management system called AIM-CHD in 1,100 adults with confirmed coronary heart disease. Half got usual care, and half used the AI system, which automatically gathered health data, assessed risk, and sent personalized feedback through a smartphone app.

After 3 months, people using the AI system had lower LDL cholesterol (the "bad" cholesterol) on average: 60.4 mg/dL versus 63.7 mg/dL in the usual care group. More importantly, 71% of AI users hit the LDL goal below 70 mg/dL, compared to 64% in the control group. They also did better on blood pressure: 45% reached the target below 130/80 mm Hg, versus 35% in the control group.

These differences were statistically significant, meaning they're unlikely to be due to chance. However, the study only lasted 3 months, and it was done at a single center. We don't know yet if these benefits last or if they translate to fewer heart attacks or strokes. Also, the study didn't report on side effects or safety issues.

Still, this is promising. It suggests that a smartphone-based AI system could be a practical way to help people with heart disease stay on track. If you're interested, talk to your doctor about what tools might work for you.

What this means for you:
An AI smartphone system helped heart patients improve cholesterol and blood pressure control in 3 months.

Common questions

What is the AIM-CHD system?

AIM-CHD is an artificial intelligence-enhanced management system. It automatically gathers health data, assesses risk based on guidelines, and sends personalized feedback to patients through a smartphone app. In this study, it was used to help people with coronary heart disease manage their cholesterol and blood pressure.

Who could benefit from this AI system?

This study involved adults with confirmed coronary heart disease. The results suggest that such a system could help this group improve their LDL cholesterol and blood pressure control. However, the study was short-term (3 months) and done at a single center, so more research is needed to know if benefits last.

How does this compare to usual care?

In this trial, the AI system led to better outcomes than usual care. For example, 71% of people using the system reached the LDL goal below 70 mg/dL, compared to 64% with usual care. For blood pressure, 45% reached the target below 130/80 mm Hg, versus 35% with usual care. These differences were statistically significant.

Are there any side effects or risks?

The study did not report on side effects, serious adverse events, or discontinuations. So we don't have information about potential risks. As with any new approach, it's important to discuss with your doctor whether it's right for you.

Study Details

Study typeRct
Sample sizen = 1
EvidenceLevel 2
Follow-up3.0 mo
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Secondary prevention of coronary heart disease (CHD) remains suboptimal due to fragmented care and therapeutic inertia. While digital health interventions offer a promising strategy, few existing tools provide comprehensive, closed-loop management of multidimensional risk factors without increasing clinician workload. This study aimed to evaluate the efficacy of an artificial intelligence (AI)-enhanced management system (AIM-CHD) in improving multidimensional risk factor control among patients with CHD. METHODS: This single-center, open-label, parallel-group, randomized clinical trial was conducted from November 2024 to June 2025 in China. A total of 1100 adults with confirmed CHD were randomized 1:1 to receive either the AIM-CHD intervention (n = 549) or usual care (n = 551) for 3 months. The AIM-CHD system featured automated multi-source data capture, guideline-directed risk stratification, and closed-loop feedback via smartphone. The primary outcome was the low-density lipoprotein cholesterol (LDL-C) level at 3 months. Secondary outcomes included goal attainment rates for LDL-C (< 70 mg/dL) and blood pressure (BP, < 130/80 mm Hg), glycated hemoglobin, smoking cessation, body mass index (BMI), medication adherence, and a composite cardiovascular endpoint at 3 months. Analysis was performed on an intention-to-treat (ITT) basis. RESULTS: Of 1100 randomized participants (mean age 61 years; 75.3% male), 943 (85.7%) completed the 3-month follow-up. The intervention group achieved a significantly lower mean LDL-C level compared with the control group (60.4 ± 23.4 vs. 63.7 ± 26.0 mg/dL), with an adjusted mean difference of - 3.2 mg/dL (95% CI, - 6.2 to - 0.3; p = 0.03). Furthermore, participants in the intervention group were more likely to achieve the LDL-C target (71% vs. 64%; RR, 1.10; 95% CI, 1.01-1.20; p = 0.03) and the BP target (45% vs. 35%; RR, 1.27; 95% CI, 1.09-1.48; p = 0.002). No significant differences were observed for HbA1c, BMI, or medication adherence. CONCLUSIONS: The AIM-CHD system significantly improved short-term lipid and BP control compared with usual care. These findings support interoperable, low-burden digital management systems as a scalable strategy in routine secondary prevention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06686056. Registered on 11 November 2024.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.